Biolegend, 504102, Purified anti-mouse IL-4 Antibody, 500μg

IL-4 is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. IL-4 is a potent lymphoid cell growth factor which stimulates the growth and activation of certain B cells and T cells. IL-4 is important for regulation of T helper subset development.
500μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Partially purified native mouse IL-4
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: ELISA Capture - Quality tested CyTOF® - Verified IP, IHC, ICC - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 0.5-2.0 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IL-4 recombinant protein ranging from 250 to 2 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: ELISA1,2,10,13 or ELISPOT5 Capture: The purified 11B11 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD6-24G2 antibody (Cat. No. 504202) as the detecting antibody and recombinant mouse IL-4 (Cat. No. 575609) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture.Neutralization1-2,9,12: The 11B11 antibody can neutralize the bioactivity of natural or recombinant IL-4. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IL-4 bioactivity in vivo and in vitro (Cat. No. 504108).Additional reported applications (for the relevant formats) include: immunoprecipitation16, immunohistochemical staining of formalin-fixed paraffin-embedded tissue sections8 and paraformaldehyde-fixed, saponin-treated frozen tissue sections6,7, and immunocytochemistry4.Note: For testing mouse IL-4 in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 431101 to 431106) are specially developed and recommended.
Application References(PubMed link indicates BioLegend citation): Shirai A, et al. 1994. Cytokine 6:329. (ELISA, Neut) Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA, Neut) Assenmacher M, et al. 1994. Eur. J. Immunol. 24:1097. Openshaw P, et al. 1995. J. Exp. Med. 182:1357. (ICC) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISA Capture) Litton M, et al. 1994. J. Immunol. Methods 175:47. (IHC) Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Hara M, et al. 2001. J. Immunol. 166:3789. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. Wang W, et al. 2007. J. Immunol. 178:4885. (Neut) Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Ohnmacht C, et al. 2008. Blood 113:2816. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Zavorotinskaya T, et al. 2003. Mol. Ther. 7:155. (IP)
Product Citations: Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed Abdel-Gadir A, et al. 2019. Nat Med. 25:1164. PubMed Lin F, et al. 2019. Sci Adv. 5:eaax1608. PubMed Berber E, et al. 2022. J Virol. 96:e0068822. PubMed Yang WL, et al. 2023. Nat Commun. 14:863. PubMed Zani F, et al. 2023. Nature. 615:705. PubMed Cai S, et al. 2020. Sci Rep. 10:14249. PubMed Liu W, et al. 2022. Stem Cells Int. 2022:1052166. PubMed Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed Fang D, et al. 2018. J Exp Med. 215:2705. PubMed Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed Yang J, et al. 2020. Front Immunol. 10:3048. PubMed Crawford G, et al. 2018. Nat Immunol. 1.388194444. PubMed Matthias J, et al. 2020. J Clin Invest. 130:4587. PubMed Singh R, et al. 2017. J Immunol. 10.4049/jimmunol.1602010. PubMed Liu W, et al. 2021. Stem Cell Res Ther. 12:153. PubMed Kaisar MMM, et al. 2018. PLoS Biol. 16:e2005504. PubMed Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed Kölle J, et al. 2022. iScience. 25:104440. PubMed Imani J, et al. 2021. JCI Insight. 6:. PubMed Wang Y, et al. 2021. Sci Transl Med. 13:. PubMed Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed Yan J, et al. 2020. Cell Rep. 107820:31. PubMed Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed He J, et al. 2021. Nat Commun. 12:4371. PubMed Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed Tan X, et al. 2021. Mol Microbiol. 116:498. PubMed Di Conza G, et al. 2021. Nat Immunol. 22:1403. PubMed Teh MR, et al. 2021. Front Immunol. 12:714613. PubMed Thornton T, et al. 2016. Nat Commun. 7:10553. PubMed Hammer A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01922. PubMed Song K, et al. 2017. Oncotarget. 8:38554. PubMed Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed Xu G, et al. 2007. J Immunol. 179:5358. PubMed Sun Y, et al. 2021. Nat Commun. 12:5147. PubMed Phan TS, et al. 2021. Sci Adv. 7:. PubMed Kaushik DK, et al. 2019. J Clin Invest. 130. PubMed Lee B, et al. 2019. Front Immunol. 0.561805556. PubMed Voehringer C 2009. Blood. 113:2816. PubMed Lee JK, et al. 2021. Cell Mol Immunol. 18:1395. PubMed Umeda M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Chen YH, et al. 2022. Arthritis Res Ther. 24:27. PubMed
RRID: AB_315315 (BioLegend Cat. No. 504101) AB_315316 (BioLegend Cat. No. 504102)
Structure: Cytokine; 15-19 kD (Mammalian)
Bioactivity: Differentiation of naïve CD4+ T cells to the TH2 type, proliferation/differentiation of activated B cells, expression of class II MHC antigens, and of low affinity IgE receptors in resting B cells
Cell Sources: Mast cells, T cells, bone marrow stromal cells
Cell Targets: B cells, T cells, monocytes, endothelial cells, fibroblasts
Receptors: Heterodimer IL-4Rα (CD124); γ-subunit (CD132) in common with IL-2R, IL-7R, IL-13R, IL-15R
Cell Type: Tregs
Biology Area: Immunology
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. Boulay J, et al. 1992. Curr. Opin. Immunol. 4:294. 3. Dullens H, et al. 1991. In vivo 5:567. 4. Paul W. 1991. Blood 77:1859.
Regulation: Upregulated by IL-2, platelet activating factor; downregulated by TGF-β
Gene ID: 16189
UniProt: View information about IL-4 on UniProt.org
Clone: 11B11
Regulatory Status: RUO
Other Names: Interleukin-4, Ia inducing factor (IaIF), B cell stimulating factor-1 (BSF-1), Hodgkin's cell growth factor (HCGF), Mast cell growth factor-2 (MCGF-2), Macrophage fusion factor (MFF), T cell growth factor-2 (TCGF-2)
Isotype: Rat IgG1, κ